REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a ...

Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close. Company management will host a conferen ...

REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held on Wednesday, June 12, 2024 at 2:00 p.m. CET at the Company's sea ...

Financial Performance - The company raised a total of €200.0 million in equity financing since inception, including €103.6 million from an IPO on Euronext in September 2020 and €75.0 million from an IPO on Nasdaq in July 2021[589]. - As of December 31, 2023, the company reported cash and cash equivalents of €21.6 million and financial assets of €36.1 million, with an accumulated deficit of €160.8 million[598]. - Net cash used in operating activities increased to €44.8 million in 2023 from €28.8 million in 2022, primarily due to higher research and development expenses[591]. - The company generated €4.3 million in revenue from activities outside the U.S. in 2023, with substantial revenue expected from the U.S. launch of the Genio product pending FDA approval[599]. - Net cash from investing activities was €32.0 million in 2023, a decrease of €122.0 million compared to €90.0 million in 2022, mainly due to changes in term accounts[592]. - The company incurred net cash from financing activities of €16.9 million in 2023, a significant increase from €(1.0) million in 2022, attributed to several capital raises[593]. - The company has consistently operated with deficits and negative cash flows since inception, with total assets reported at €124.2 million as of December 31, 2023[598]. Research and Development - The company expects research and development expenses to continue increasing as it hires personnel and invests in next-generation innovations of the Genio system[597]. - The total number of employees increased to 146.8 in 2023 from 137.5 in 2022, representing a growth of 9.5%[689]. - Research & Development employees rose to 106.4 in 2023, up from 102.6 in 2022, indicating a 3.7% increase[689]. Corporate Governance and Board Structure - The company has a board of directors that includes independent directors as per Nasdaq listing requirements[652]. - The audit committee consists of three independent directors, ensuring compliance with both Nasdaq and Belgian Code on Corporate Governance[668]. - The remuneration committee is chaired by a non-executive director and consists of a majority of independent directors[673]. - The nomination committee also consists of a majority of independent directors, ensuring governance standards are met[678]. - The science & technology committee assists the board in matters related to technological advancements and innovations[679]. - The board of directors is responsible for risk management oversight, delegating day-to-day risk management to management[653]. - The company has established a "one tier" governance structure for effective decision-making and management control[656]. - The company has no independent internal audit function, which is a deviation from the Belgian Code on Corporate Governance, justified by the company's size[685]. - The corporate governance charter is regularly updated to reflect changes in corporate governance standards and practices[687]. Director and Executive Compensation - The annual fixed fee for the Chairman – Non-Executive Director is €82,000, while Independent and Non-Executive Directors receive €45,000 each[621]. - The additional fee for Audit Committee Members is €9,000, and for Remuneration, Science & Technology, and Nominating and Corporate Governance Committee Members, it is €4,500 each[621]. - For the year ended December 31, 2023, Robert Taub earned €127,633, while Pierre Gianello, M.D. earned €175,634[625]. - The remuneration of the chief executive officer and other executive management members is based on recommendations from the remuneration committee[629]. - The chairman of the Audit Committee received remuneration at a rate equal to an annual fixed fee of €18,000[621]. - The total compensation for directors includes reimbursement for reasonable out-of-pocket expenses incurred in performing their duties[622]. - The target proportion of the executive management's remuneration consists of one third fixed base salary, one third short-term incentives, and one third long-term incentives[634]. - Olivier Taelman's total compensation for 2023 was €807,096, which includes a base salary of €436,351 and a performance bonus of €301,500[637]. - Loïc Moreau's total compensation for 2023 was €468,887, which includes a base salary of €258,877 and a performance bonus of €183,807[638]. - In 2023, Olivier Taelman was granted 25,000 warrants under the 2021 Warrants Plan, while Loïc Moreau received 15,284 warrants[637][638]. - The company maintains liability insurance for its directors and executive management team to cover potential damages and expenses[642]. Warrant Plans and Share Options - All non-executive directors were granted 25,000 warrants under the 2021 Warrants Plan, with Wildman Ventures LLC receiving 11,389 warrants under the 2021 plan and 13,602 under the 2022 plan[626]. - The exercise price for the warrants held by directors ranges from €7.19 to €12.95, with expiration dates between June 8, 2027, and June 14, 2028[628]. - The exercise price for the warrants issued under the 2021 Warrants Plan is €5.42, with an expiration date of March 24, 2028[641]. - The company has established multiple warrant plans, with the 2021 Warrants Plan being the most recent, allowing for the issuance of warrants to employees and executives[646]. - The company granted a total of 595,167 2021 Warrants accepted in 2021, 2022, and 2023[8]. - The subscription price for the 2018 Warrants granted in July 2019 is €6.52 per new share[1]. - The subscription price for the 2018 Warrants granted in April 2020 is €11.93 per new share[2]. Diversity and Inclusion - The board of directors includes 2 female and 6 male directors, with 1 underrepresented individual in the home country jurisdiction[682]. - The company has a focus on diversity and inclusion initiatives to attract and retain top talent necessary for long-term success[693]. - The company believes that share-based incentives for non-executive directors align their interests with shareholders, despite deviations from the Belgian Code[685]. Currency Risk Exposure - The company does not hedge its currency risk exposure, which may lead to variability in earnings due to foreign exchange fluctuations[830]. - If the USD strengthens by 5% against the Euro, the net loss for 2023 would be €54,000 lower, while a 5% weakening would increase the net loss by €60,000[829].

Exhibit 99.1 REGULATED INFOMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), April 20, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Together Partnership On April 18, 2023, Nyxoah received a transparency notification from Together Partnership following the crossing of th ...

Nyxoah S.A. (NASDAQ:NYXH) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Olivier Taelman - Chief Executive Officer Loïc Moreau - Chief Financial Officer Conference Call Participants Adam Maeder - PSC Jon Block - Stifel Suraj Kalia - Oppenheimer Operator Thank you for standing by. And welcome to the Nyxoah Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answe ...

Table of Contents As filed with the Securities and Exchange Commission on March 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

[Executive Summary](index=1&type=section&id=Executive%20Summary) [Company Overview](index=1&type=section&id=Company%20Overview) Nyxoah SA is a medical technology company focused on developing and commercializing innovative solutions for Obstructive Sleep Apnea (OSA), reporting its financial and operating results for the fourth quarter and full year 2022 - Nyxoah SA is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA)[3](index=3&type=chunk) [Recent Financial and Operating Highlights](index=1&type=section&id=Recent%20Financial%20and%20Operating%20Highlights) Nyxoah achieved significant milestones in Q4 and FY 2022, including completing all 115 implants in the DREAM U.S. pivotal study, filing the first PMA module, and demonstrating positive preliminary 12-month data for early DREAM patients. Commercially, the company saw substantial sales growth and market share gains in Germany, strengthening its supply chain and initiating the ACCCESS U.S. IDE study - Completed all **115 implants** in the DREAM U.S. pivotal trial, with 12-month data expected early next year[6](index=6&type=chunk) - Filed the first module in the modular PMA submission[6](index=6&type=chunk) - Submitted 12-month data on the first **34 DREAM patients** to SLEEP 2023, demonstrating a **65% AHI responder rate** and a **76% ODI responder rate**[6](index=6&type=chunk) Commercial Performance Highlights | Metric | Q4 2022 | Change/Status | | :-------------------------- | :---------- | :------------ | | Quarterly Sales | €1.3 million | Sequential German market share gain | | Active German Accounts (End of Year) | 38 | Up from 12 entering 2022 | - Strengthened supply chain with Belgium manufacturing facility receiving clearance from the EU notified body[6](index=6&type=chunk) - Implanted the first patients in the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC), with implant completion expected in **2024**[6](index=6&type=chunk) Cash Position | Metric | End of 2022 | | :---------------- | :---------- | | Total Cash Position | €94.8 million | [2023 Key Objectives](index=1&type=section&id=2023%20Key%20Objectives) For 2023, Nyxoah aims to focus on patient follow-up in the DREAM study to achieve primary endpoints, prepare for U.S. regulatory approval, manufacturing, and market access, and further accelerate revenue and market share growth in Germany - Focus on patient follow-up in the DREAM study resulting in reaching the primary endpoints[6](index=6&type=chunk) - U.S. regulatory, manufacturing and market access readiness[6](index=6&type=chunk) - Drive further revenue and market share growth in Germany[6](index=6&type=chunk) [Fourth Quarter and Full Year 2022 Financial Results](index=2&type=section&id=Fourth%20Quarter%20and%20Full%20Year%202022%20Results) [Consolidated Statements of Loss and Other Comprehensive Loss](index=2&type=section&id=Consolidated%20Statements%20of%20Loss%20and%20Other%20Comprehensive%20Loss) Nyxoah reported significant revenue growth in Q4 and FY 2022, but also experienced increased operating and net losses due to substantial investments in research and development, as well as selling, general, and administrative expenses Consolidated Statements of Loss and Other Comprehensive Loss (in thousands €) | Metric | Q4 2022 | Q4 2021 | FY 2022 | FY 2021 | | :------------------------------------ | :------ | :------ | :------ | :------ | | Revenue | 1,307 | 295 | 3,084 | 852 | | Cost of goods sold | (465) | (105) | (1,150) | (303) | | Gross profit | 842 | 190 | 1,934 | 549 | | Research and Development Expense | (4,575) | (3,335) | (15,861) | (12,344) | | Selling, General and Administrative Expense | (5,363) | (3,937) | (18,855) | (14,712) | | Operating loss for the period | (9,050) | (6,543) | (32,499) | (26,242) | | Loss for the period | (13,296) | (6,248) | (31,225) | (27,619) | | Basic loss per share (in EUR) | (514) | (238) | (1,209) | (1,161) | [Consolidated Statement of Financial Position](index=3&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As of December 31, 2022, Nyxoah's total assets decreased to €146.1 million from €170.8 million in 2021, primarily driven by a significant reduction in cash and cash equivalents, despite an increase in intangible assets. Total equity attributable to shareholders also declined Consolidated Statement of Financial Position (in thousands €) | Metric | Dec 31, 2022 | Dec 31, 2021 | | :-------------------------------- | :----------- | :----------- | | **ASSETS** | | | | Non-current assets | 45,811 | 30,770 | | Current assets | 100,260 | 140,060 | | Total assets | 146,071 | 170,830 | | **EQUITY AND LIABILITIES** | | | | Total equity attributable to shareholders | 120,324 | 148,622 | | Total liabilities | 25,747 | 22,208 | | Total equity and liabilities | 146,071 | 170,830 | - Cash and cash equivalents decreased from **€135,509 thousand** in 2021 to **€17,888 thousand** in 2022[11](index=11&type=chunk) - Intangible assets increased from **€25,322 thousand** in 2021 to **€39,972 thousand** in 2022[11](index=11&type=chunk) [Revenue Analysis](index=4&type=section&id=Revenue) Nyxoah's revenue significantly increased in Q4 2022 to €1.3 million (from €295,000 in Q4 2021) and for the full year 2022 to €3.1 million (from €0.9 million in 2021), primarily driven by the commercialization of the Genio® system, particularly in Germany Revenue Performance (in thousands €) | Period | 2022 Revenue | 2021 Revenue | YoY Change | | :------- | :----------- | :----------- | :--------- | | Q4 | 1,307 | 295 | +343% | | Full Year | 3,084 | 852 | +262% | - The increase in revenue was attributable to the Company's commercialization of the Genio® system, primarily in Germany[13](index=13&type=chunk) [Cost of Goods Sold and Gross Profit Analysis](index=4&type=section&id=Cost%20of%20Goods%20Sold) Cost of goods sold increased in Q4 and FY 2022, reflecting higher revenue. Gross profit also rose, with gross margin remaining stable at 64.4% for Q4 2022 and slightly decreasing to 62.7% for the full year 2022 Cost of Goods Sold and Gross Profit (in thousands €) | Metric | Q4 2022 | Q4 2021 | FY 2022 | FY 2021 | | :----------------- | :------ | :------ | :------ | :------ | | Cost of goods sold | 465 | 105 | 1,150 | 303 | | Gross profit | 842 | 190 | 1,934 | 549 | | Gross margin | 64.4% | 64.4% | 62.7% | 64.4% | [Operating Expenses Analysis](index=4&type=section&id=Operating%20Expenses%20Analysis) Operating expenses, including R&D and SG&A, saw substantial increases in 2022, driven by investments in next-generation product development, ongoing clinical studies (DREAM), expanded commercial efforts in Europe, and corporate infrastructure build-out for the anticipated U.S. launch [Research and Development Expenses](index=4&type=section&id=Research%20and%20Development%20Expenses) Research and Development Expenses (in thousands €) | Period | 2022 Expense | 2021 Expense | YoY Change | | :------- | :----------- | :----------- | :--------- | | Q4 | 4,575 | 3,335 | +37.2% | | Full Year | 15,861 | 12,344 | +28.5% | - The increase reflects investments in the development of next-generation versions of the Genio® system and ongoing clinical studies, most notably DREAM in the U.S.[16](index=16&type=chunk) [Selling, General and Administrative Expenses](index=5&type=section&id=Selling%2C%20General%20and%20Administrative%20Expenses) Selling, General and Administrative Expenses (in thousands €) | Period | 2022 Expense | 2021 Expense | YoY Change | | :------- | :----------- | :----------- | :--------- | | Q4 | 5,363 | 3,937 | +36.2% | | Full Year | 18,855 | 14,712 | +28.2% | - The increase was primarily due to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah's corporate infrastructure ahead of the U.S. commercial launch[19](index=19&type=chunk)[20](index=20&type=chunk) [Operating Loss](index=5&type=section&id=Operating%20Loss) Nyxoah's operating loss widened to €9.1 million for Q4 2022 and €32.5 million for the full year 2022, up from €6.5 million and €26.2 million respectively in 2021, driven by accelerated R&D spending and ongoing commercial and clinical activities Operating Loss (in thousands €) | Period | 2022 Operating Loss | 2021 Operating Loss | YoY Change | | :------- | :------------------ | :------------------ | :--------- | | Q4 | (9,050) | (6,543) | +38.3% | | Full Year | (32,499) | (26,242) | +23.8% | - The increased operating loss was driven by the acceleration in the Company's R&D spending, as well as ongoing commercial and clinical activities[21](index=21&type=chunk) [Cash Position](index=5&type=section&id=Cash%20Position) As of December 31, 2022, Nyxoah's total cash and financial assets decreased to €95 million from €135.5 million at the end of 2021, reflecting an average monthly cash burn of approximately €3.4 million during 2022 Cash and Financial Assets (in millions €) | Metric | Dec 31, 2022 | Dec 31, 2021 | Change | | :------------------------ | :----------- | :----------- | :----- | | Cash and Financial Assets | 95.0 | 135.5 | -40.5 | | Monthly Cash Burn (2022) | 3.4 | N/A | N/A | [Additional Information](index=5&type=section&id=Additional%20Information) [Full Year Report & Conference Call Details](index=5&type=section&id=Full%20Year%20Report%20%26%20Conference%20Call%20Details) The full audited consolidated results for 2022 are available on Nyxoah's investor website, and a conference call and webcast were held on March 22, 2023, to discuss these results - Nyxoah's financial report for the full year of **2022**, including details of the audited consolidated results, are available on the investor page of Nyxoah's website[23](index=23&type=chunk) - A conference call and webcast presentation were scheduled for **March 22, 2023**, at **10:30pm CET / 4:30pm ET**[24](index=24&type=chunk) [About Nyxoah](index=6&type=section&id=About%20Nyxoah) Nyxoah is a medical technology company focused on Obstructive Sleep Apnea (OSA), with its Genio® system as a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy. The Genio® system holds European CE Mark approval, including an expanded indication for Complete Concentric Collapse (CCC) patients, and is currently undergoing the DREAM IDE pivotal study for U.S. FDA approval - Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA)[26](index=26&type=chunk) - Nyxoah's lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA[26](index=26&type=chunk) - The Genio® system received its European CE Mark in **2019** and CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients[27](index=27&type=chunk) - The Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval[27](index=27&type=chunk) [Forward-looking Statements](index=6&type=section&id=Forward-looking%20statements) This section contains forward-looking statements reflecting the company's current expectations regarding its Genio® system, clinical studies, regulatory pathways, and financial performance, which are inherently subject to various risks, uncertainties, and assumptions that could cause actual results to differ materially - Forward-looking statements reflect the Company's current expectations regarding the Genio® system, planned and ongoing clinical studies, potential advantages, regulatory pathway, and financial outlook[29](index=29&type=chunk) - These statements involve risks, uncertainties, assumptions, and other factors that could cause actual results or events to differ materially from those expressed or implied[29](index=29&type=chunk) - Risks and uncertainties include those set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended **December 31, 2021**[29](index=29&type=chunk) [Contacts](index=6&type=section&id=Contacts) Contact information for Nyxoah's Chief Strategy Officer, David DeMartino, is provided for inquiries - Contact for Nyxoah is **David DeMartino**, Chief Strategy Officer[30](index=30&type=chunk)

Nyxoah S.A. (NASDAQ:NYXH) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jeremy Feffer - Vice President, Investor Relations Olivier Taelman - Chief Executive Officer Loïc Moreau - Chief Financial Officer Conference Call Participants Simran Kaur - Piper Sandler Jonathan Block - Stifel Nicolaus Ross Osborn - Cantor Fitzgerald Operator Good day. And thank you for standing by. Welcome to the Nyxoah Third Quarter 2022 Conference Call. [Operator Instructions] Please be a ...

Nyxoah S.A. (NASDAQ:NYXH) Q2 2022 Results Conference Call August 8, 2022 4:30 PM ET Â Company Participants Jeremy Feffer - VP, IR Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Simran Kaur - Piper Sandler Suraj Kalia - OpCo Operator Good day, and thank you for standing by. Welcome to the Nyxoah Second Quarter '22 Conference Call. [Operator Instructions] Please be advised, todayÂ's conference is being recorded. I would like to hand the conference call to ...